GSK China Experiences Leadership Transition: A New Era Begins

2024-05-11

疫苗高管变更财报

In a significant development for GSK China, the pharmaceutical giant has undergone a leadership transition, marking the start of a new era. According to reports, Cecilia Qi, the current Vice President and General Manager of GSK China, has been appointed as the Vice President and Head of Vaccines for GSK Greater China and Intercontinental Region. Meanwhile, Sherman Yu, the Vice President and General Manager of GSK Taiwan, will assume the role of Vice President and General Manager of GSK China. This transition is set to take effect on June 1, with both executives assuming their new positions on July 1.

Cecilia Qi's Achievements and Background:

Cecilia Qi, a graduate of Shanghai Jiao Tong University School of Medicine, has a wealth of experience in the pharmaceutical industry. She has held various positions in multinational companies such as Shiseido, Pfizer, Sanofi, and Merck. Qi joined GSK China in 2004 as the Market Director for the Vaccine Business. Over the years, she has taken on roles such as General Manager of the Hepatitis Business Unit and Head of Digital Marketing and Commercial Excellence. In 2017, she was appointed as the General Manager for GSK Hong Kong and Macau and later promoted to Vice President and General Manager of GSK China's Vaccine Business. With her leadership, GSK China has achieved significant milestones, including the approval and launch of 21 new products and indications, while maintaining consistent growth.

Sherman Yu's Professional Background:

Sherman Yu is a seasoned professional in the pharmaceutical field. Earlier in her career, she held positions in business management and marketing at Wyeth and Pfizer Vaccines. In 2012, Yu joined GSK as the General Manager for Hong Kong and subsequently took on additional responsibilities for GSK's business in Taiwan. In May 2019, she was appointed as the Chief Operating Officer for GSK Greater China. Under Yu's leadership, GSK Taiwan achieved remarkable performance growth, particularly in the vaccine business, including successful market launches of vaccines such as Shingrix and accelerated approvals for Arexvy.

GSK's Strategic Focus on the Chinese Market:

The Chinese market has always been a strategic focus for GSK. In January of this year, the company reorganized its operations in China, establishing three core business units: Specialty Care, Vaccines, and Respiratory. The newly appointed leadership team is committed to positioning GSK China among the top ten multinational pharmaceutical companies in China by 2030.

Financial Performance and Growth:

GSK's first-quarter financial report, released on May 1, showcased promising results. The company generated total revenue of £7.367 billion, with a year-on-year growth of 10%. Excluding the impact of COVID-19-related products, the revenue growth stood at 13%. Notably, the vaccine business emerged as a key driver of growth, with sales of RSV vaccine Arexvy reaching £182 million, representing a 22% increase, and sales of shingles vaccine Arexvy reaching £945 million, reflecting an 18% increase.

With the appointment of Cecilia Qi as the Vice President and Head of Vaccines for GSK Greater China and Intercontinental Region, and Sherman Yu as the Vice President and General Manager of GSK China, GSK is poised for a new chapter in its journey in China. Their collective expertise and strategic vision are expected to drive further growth and solidify GSK's position as a leader in the Chinese pharmaceutical market. As GSK embraces this leadership transition, it prepares to continue its commitment to innovation, healthcare advancement, and improving the lives of patients in China and beyond.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构